Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open-Label Study
The Future of Oral Antivirals: VV116 and the Promise of Targeted COVID-19 Treatment The quest for effective and convenient oral treatments for COVID-19 continues, with VV116 (too known as Mindvy or JT001) emerging as a promising candidate. This novel drug, a deuterated form of remdesivir hydrobromide, is undergoing rigorous testing to determine its efficacy and … Read more